Ovarian cancer screening: Recommandations for clinical pratice;Dépistage du cancer de l'ovaire: Recommandations pour la pratique clinique

Revue Medicale Suisse

Volumn 6, Issue 250, 2010, Pages 1062-1068

  Amram Benamran, Marie Laure ^a   Cochet, Stephane ^a   Sappino, André Pascal ^a   Petignat, Patrick ^b  

^a Service d'Oncologie   (Switzerland)

^b HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; TUMOR MARKER;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EXAMINATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; GENETIC SCREENING; HUMAN; ORAL CONTRACEPTION; OVARIECTOMY; OVARY CANCER; PRACTICE GUIDELINE; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; TRANSVAGINAL ECHOGRAPHY;

FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 77953423405     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Roett MA, Evans P. Ovarian cancer: An overview. Am Fam Physician 2009;80:609-16.
2. Whittemore AS. Characteristics relating to ovarian cancer risk: Implications for prevention and detection. Gynecol Oncol 1994;55:S15-9.
3. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
4. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-16.
5. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer staging manual. 6th ed. New York: Springer, 2002;275-84.
6. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2006;95(Suppl. I):S161-91
7. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: Possibilities for earlier detection. Cancer 2007;109:221-7.
8. ** Clarke-Pearson DL. Screening for ovarian cancer. N Engl J Med 2009;361:170-1.
9. Fleischer AC, Cullinan JA, Kepple DM, et al. Conventional and color Doppler transvaginal sonography of pelvic masses: A comparison of relative histologic specificities. J Ultrasound Med 1993;12:705-12.
10. Stein SM, Laifer-Narin S, Johnson MB, et al. Differentiation of benign and malignant adnexal masses: Relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 1995;164:381-6.
11. Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: The contribution of Doppler ultrasound. Ultrasound Obstet Gynecol 1999;14:338-47.
12. Carter JR, Lau M, Fowler JM, et al. Blood flow characteristics of ovarian tumors: Implications for ovarian cancer screening. Am J Obstet Gynecol 1995;172:901-7.
13. Bast RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
14. Jacobs I, Bast RC. The CA125 tumour-associated antigen: A review of the literature. Hum Reprod 1989;4:1-12.
15. Woolas RP, Xu FJ, Jacobs IJ, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993;85:1748-51.
16. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72. Errata, Clin Cancer Res 2008;14:5308,7158.
17. ** U.S. preventive services task force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement Published correction in Ann Intern Med 2005;143:547. Ann Intern Med 2005;143:355-61.
18. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259-72.
19. ** National comprehensive cancer network practice guidelines in oncology: Ovarian cancer and genetic screening. (Available at www.nccn.org/professionals/physician-gls/PDF/genetics-screening.pdf).
20. ** MacLennan AH, Baber R. Hormone therapy use and risk of ovarian cancer. JAMA 2009;302:2203.
21. Collaborative group on epidemiological studies of ovarian cancer. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23'257 women with ovarian cancer and 87'303 controls. Lancet 2008;371:303-14.